|1.||Komamura, Kazuo: 2 articles (12/2006 - 10/2005)|
|2.||Ueno, Kazuyuki: 2 articles (12/2006 - 10/2005)|
|3.||Kitakaze, Masafumi: 2 articles (12/2006 - 10/2005)|
|4.||Fukumoto, Kyoko: 2 articles (12/2006 - 10/2005)|
|5.||Kamakura, Shiro: 2 articles (12/2006 - 10/2005)|
|6.||Kasanuki, H: 2 articles (11/2001 - 10/2001)|
|7.||Shiga, T: 2 articles (11/2001 - 10/2001)|
|8.||Papp, Julius Gy: 1 article (09/2015)|
|9.||Leprán, István: 1 article (09/2015)|
|10.||Varró, András: 1 article (09/2015)|
01/01/1989 - "Antiarrhythmic effects of desethylamiodarone in dogs with subacute myocardial infarction and inducible ventricular arrhythmias."
01/01/1988 - "The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction."
09/01/2015 - "The aim of this investigation was to compare the effectiveness of long-term pretreatment with amiodarone (AMIO) and its active metabolite desethylamiodarone (DEA) on arrhythmias induced by acute myocardial infarction in rats. "
01/01/1989 - "To determine if desethylamiodarone (DA), the principal metabolite of amiodarone, has antiarrhythmic activity, DA was administered intravenously (i.v.) as a 5 mg/kg bolus followed by a 2-h infusion of 8 mg/kg/h to 12 dogs with 5-7-day-old myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. "
11/01/1987 - "The autopsy tissues concentration of amiodarone and desethylamiodarone of a man with acute myocardial infarction treated acutely with intravenous amiodarone is reported. "
|2.||Cardiac Arrhythmias (Arrythmia)
10/01/2005 - "To evaluate the pharmacokinetic properties and an optimum dose schedule of amiodarone in long-term oral therapy, serum concentrations of amiodarone and its metabolite, desethylamiodarone, were monitored from 345 Japanese inpatients who received amiodarone therapy for a variety of cardiac arrhythmias. "
05/01/1987 - "Amiodarone and desethylamiodarone plasma concentrations and the effects of the drug on conduction intervals or right ventricular effective refractory periods were not related to suppression of arrhythmia induction by ventricular stimulation after 1 month of therapy. "
01/01/1985 - "At the time of reduction in the arrhythmia frequency, tissue levels of both amiodarone and desethylamiodarone in the border and infarct zone of the myocardium were approximately 50% as high as in the normal zone. "
01/01/1984 - "The concentrations of amiodarone (Cordarone) and desethylamiodarone in plasma after single oral and intravenous and long-term oral dosing were determined in seven normal subjects and 106 patients with various cardiac arrhythmias, respectively, using a high-performance liquid chromatographic method. "
06/01/1992 - "The decrease in TLCO was found to be significantly related to an increasing cumulated dose of amiodarone (p = 0.007), whereas the reduction in TLCO was found to be unrelated to sex, age, underlying heart disease, arrhythmia, daily dose of amiodarone, duration of treatment, plasma concentration of amiodarone and desethylamiodarone, and pretreatment pulmonary function abnormalities. "
|3.||Left Ventricular Dysfunction
08/01/1996 - "To evaluate the potential need for modification of dose regimens of intravenous amiodarone in patients with left ventricular dysfunction, the pharmacokinetics of amiodarone and its active metabolite, desethylamiodarone (DEA), were examined after a single 15-minute intravenous infusion of amiodarone 5 mg/kg. Three parallel groups of otherwise healthy volunteers with normal (n = 12), moderately impaired (ejection fraction > 30 but < or = 45%; n = 6), or severely impaired (ejection fraction < or = 30%; n = 6) left ventricular function were enrolled in the study. "
04/01/2007 - "To study the effect of hyperlipoproteinemia on in vitro distribution of amiodarone (AM) and its prevalent metabolite desethylamiodarone (DEA) in human and rat plasma. "
04/01/2007 - "The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma."
|7.||Sotalol (Sotalol Hydrochloride)
|3.||Cardiopulmonary Bypass (Heart-Lung Bypass)